New SAMHSA paper offers a comprehensive roadmap for psychedelic medicines
The US Federal agency Substance Abuse and Mental Health Services Administration (SAMHSA) has published a new technical assistance paper, Current research, regulatory, and policy considerations regarding psychedelics as medicine, as part of its Mental Health Innovations Series. Although the paper was prepared for the US policy context, it is one of the most useful and comprehensive overviews currently available for anyone thinking seriously about how psychedelic medicines may move from research into health systems.
The document is especially relevant for European healthcare policymakers, regulators, payers, service commissioners, health system planners, and clinical providers. Many of the questions it raises are not US-specific: how to prepare for possible regulatory approvals, how to structure safe delivery models, what workforce and facility requirements may be needed, how reimbursement could work, how to manage ethical risks, and how to protect patients in a field where unregulated access is already expanding.
The paper places these issues in the context of a rapidly changing US policy landscape. In April 2026, an executive order on Accelerating Medical Treatments for Serious Mental Illness directed federal agencies to accelerate psychedelic research and access, including priority review vouchers for psychedelic drug applications, expanded right-to-try access for eligible psychedelic drugs including ibogaine, $50 million in federal funding through ARPA-H, and faster scheduling processes for approved psychedelics that complete Phase 3 trials for serious mental health conditions.
The regulatory pipeline is also moving quickly. The paper notes that psilocybin has completed two pivotal Phase 3 trials for treatment-resistant depression and remains the most advanced classic psychedelic in the FDA development pathway. It also reviews other late-stage or fast-moving programmes, including MDMA for PTSD, LSD for generalized anxiety disorder, deuterated psilocin for major depressive disorder, 5-MeO-DMT for treatment-resistant depression, methylone for PTSD, and others. Several of these have received FDA Breakthrough Therapy Designations, while priority review vouchers could shorten review timelines from the usual 10–12 months to as little as 1–2 months.
What makes the paper particularly valuable is that it does not treat regulatory approval as the endpoint. Instead, it looks at what health systems would actually need to deliver these treatments responsibly. It discusses the difference between psychological support and psychotherapy, safety monitoring, informed consent, contraindications, workforce training, facility requirements, Medicaid and insurance questions, and the need for oversight frameworks before treatments become widely available.
This is highly relevant for Europe. If psychedelic therapies are approved in the US in the near future, European systems will likely face growing pressure from patients, clinicians, researchers, and policymakers to clarify their own regulatory, reimbursement, and access pathways. The SAMHSA paper is a useful reminder that the real challenge is not only whether psychedelic medicines work, but whether health systems are ready to deliver them safely, equitably, and sustainably.
The paper also strikes an appropriately cautious tone. It recognises the promise of psychedelic therapies, while clearly noting that evidence remains uneven, that many trials have excluded people with serious mental illness, low incomes, and complex trauma histories, and that long-term durability, real-world implementation, and comparative effectiveness still require more research.
For European decision-makers, this is exactly the kind of practical, system-level thinking that will be needed in the coming years. As the field moves closer to possible approvals, preparation should not wait until the first product reaches the market.
